Connect with us

NEWS

New Age Farm Inc (OTCMKTS:NWGFF) To Expand Its Reach In Cannabis Market

Published

on

New Age Farm Inc (OTCMKTS:NWGFF) has finalized a deal to buy a stake of up to 37.5% in Trellis Holdings Oregon Op LLC. This deal is expected to increase the company’s presence in cannabis cultivation market. Trellis presently operates on one of the legal areas of the firm’s Cave Junction, Oregon property. It also has an OLCC licence for the cultivation of recreational cannabis on area of 40,000 square feet.

The buzz

New Age reported that they are working on negotiating the terms of the deal with Trellis. The finalized letter of intent has a 60-day term for due diligence. This deal is subject to approval from the existing members of Trellis. The company reported that Trellis intends to grow the cultivation to inhabit another allowed plot on the Cave Junction property. Trellis also runs a licensed retail outlet at its Portland, Oregon property.

The deal between New Age and Trellis is stated as a “related party transaction” as mentioned under “MI 61-101”. It is exempt from the official valuation and minority shareholder support requirements of “MI 61-101” as the fair market value of the deal does not surpass 25% of the firm’s market capitalization.

In the month of August, New Age Farm clarified on the news release posted pertaining to its two marijuana asset acquisitions in Oregon. The first property in discussion was Cave Junction in the state of Oregon. This property was spread on 11 acres divided into two distinct legal lots. It was converted into an advanced greenhouse cannabis grow facility in 2015. Since then, Cave Junction has been managed by Trellis Farms.

Another property in discussion is in Portland, Oregon. This property comes in the list of established dispensaries in the region. Portland asset has recorded considerable success in the last four years in Oregon and is currently run by an OLCC licensed retailer.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

NEWS

Delta 9 Cannabis Inc. (OTCMKTS: DLTNF) Unveils Vaccination reward Program to Encourage Manitobans to Receive COVID-19 Vaccine

Published

on

Delta 9 Cannabis Inc. (OTCMKTS: DLTNF) has announced the Delta 9 “Joint for Jabs” program, a vaccination reward program, to encourages residents of Manitoba to receive the two doses of the COVID-19 vaccine to be fully vaccinated. 

Delta 9 Cannabis launch rewards program 

The program started on June 21, 2021, and people that had received both doses of the COVID-19 vaccine will be eligible to enter the rewards program at its locations in Manitoba. The company employs several Manitobans in the province, and the company hopes to help in the reopening of the local communities. 

John Arbuthnot, the company’s CEO, said, “We want to encourage all Manitobans to get vaccinated as soon as possible to help ensure that we can all get back to doing the things we love with our friends and family. Our hope is that the “Joints for Jabs” program will contribute to achieve this objective.”

The rewards program is tiered with prize draws expected to be held monthly. In addition, there are three grand prize draws in which a customer will receive One year of Supply of Cannabis, 20  free joints every month at the company’s stores in Manitoba, and Delta 9 Branded Apparel giveaways. 

Delta 9 Cannabis announces expansion to Newfoundland

Recently, the company announced that Oceanic Releaf Inc., its strategic partner, had received five cannabis retail licenses in Labrador and Newfoundland provinces. Delta 9 Cannabis owns a 5% stake in Oceanic’s current retail store and expansion plans and production facility operations. 

Arbuthnot said that they are looking forward to expanding their presence in Newfoundland. He said that opening five new Oceanic stores in Newfoundland would enable the company to get insight into customers’ buying preferences to assist in tailoring products for the local market. 

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Featured

Vapor Group Inc (OTCMKTS:VPOR) Business Model Paying Off As Orders for Isolate CBD Stream In

Published

on

Vapor Group Inc (OTCMKTS:VPOR) is evidently having a spectacular run following the adoption of a new business model early this year focused on the lucrative CBD industry estimated to be worth well over $16 billion. The company recently secured $80,000 order for its premium CBD isolate bringing the total tally of orders to $600,000 this year alone.

$500,000 in under 3 months

As of April this year, the company had reportedly secured orders totaling about $500,000. In its Q1 2019 earnings, VPOR reported a number of high-profile business deals from reputable names in the industry including White Label liquid and GenCanna global, Inc among others. The company’s biggest purchase order thus far came in May when industry titan, Diamond CBD owned by potNetwork holdings placed a hefty $210,000 order for its bulk CBD isolate.

Vapor bills itself as the provider of industry grade CBD isolate famed for its high potency and purity. The product is developed in the company’s state-of-art manufacturing facilities that utilize sophisticated nanotechnology to deliver a premium end product sought after by industry leaders. The trickling enormous purchase orders are testimony of the product’s unparalleled effectiveness.

Sophisticated manufacturing

The company’s products are manufactured from 100% organic hemp sourced from the best growers in the United States from the states of Colorado, Kentucky, and Oregon. VPOR is constantly researching and experimenting on new processing methods and techniques to stay at par with the industry’s dynamic trends.

VPOR’s President and CEO, David Zinger is confident that the company is on course to becoming the premium suppliers of industry-level CBD isolate. Zinger credits the company’s success to over the past few months to “smart planning and strategizing.” Further, he is optimistic that with the continued sustainable growth, the will be able to provide long-term value to their stakeholders.

Positive trends witnessed in the CBD industry points to a lucrative future for players in the sector including Vapor. Reportedly, 7% of Americans are using CBD products now with the number expected to spike by 10% come 2025.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Featured

Medical Marijuana Inc. (OTCMKTS:MJNA) Authorized To Offer CBD Products In Bulgaria

Published

on

Medical Marijuana Inc. (OTCMKTS:MJNA) has announced that it has been granted authorization to sell its hemp derived CBD products in Bulgaria.

Medical Marijuana receives authorization for CBD products in Bulgaria

Blake Schroeder the CEO of Kannaway stated that they are delighted to continue paving the way for CBD acceptance in Bulgaria to follow suit with what is happening in the rest of the world. The CEO added that following the authorization they were hoping to position themselves in the Bulgarian market and become leaders in CBD education across Europe.

The authorization means that Kannaway’s goods will be freely sold in Bulgaria and they are equally approved for export.  Kannaway VP Alex Grapov said that the company was looking forward to trailblazing the global CBD market as advocates of its benefits. He added that they have met with regulatory bodies to makes sure that the company’s operations are within the purview of the law thus creating an avenue for customers and brand ambassadors.

Publication of CBD research on CIPN in Molecular Sciences Journal

Last week Medical Marijuana announced that its portfolio company Kannalife Inc. (OTCMKTS: KLFE) had published its findings on Chemotherapy-Induced Peripheral Neuropathy in the Molecular Neuroscience Journal.  Market Study Report LLC has indicated that the international market for CIPN treatment is expected to exceed $1.88 billion by 2024. Kannalife expects clinical trials for its CBD-like molecule KLS-13019 as a therapeutic treatment for CIPN to commence in the second quarter of 2020.

Medical Marijuana CEO Stuart Titus said that CIPN affects around 30% to 405 of patients undergoing chemotherapy adding that they were pleased to support Kannalife in its research to discover a treatment alternative for such patients.

Kannalife was funded by the National Institute on Drug Abuse to work on the research. The grant permits the research in the development of KLS-13019 in CIPN and drug dependence. Kannalife has the obligation to study important advancements that involve identification of the mechanisms that bring CIPN and the application o0f study results in designing on novel treatment approaches for neuropathic pain and use of the approaches in reducing opioid prescription and opioid abuse.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories